Market Overview

Using the Technology That Powers GPS Cancer™, Scientists Have Developed Fresh Insights into the Driving Mechanisms of a Rare Skin Cancer

Share:

Peer-reviewed research utilizing NantOmics technology gives
scientists fresh insights into driving mechanisms behind a form of rare
skin cancer

New, peer-reviewed research utilizing NantOmics technology, which powers
NantHealth's (NASDAQ:NH) GPS Cancer ® is giving scientists fresh
insights into the driving mechanisms behind a form of rare skin cancer
as well as therapies to treat patients.

Scientists from NantOmics as well as the University of California San
Francisco and Thomas Jefferson University in Philadelphia published that
chronic inflammation caused by a rare, inherited childhood skin disorder
known as recessive dystrophic epidermolysis bullosa (RDEB) can lead to
cancer.

The research was published in the journal Science Translational Medicine.

NantOmics,
LLC
, is a leader in molecular analysis and a member of the NantWorks,
LLC
ecosystem of families.

The research also found that inflammation from chronic skin injury can
trigger DNA mutations and cancer in much the same way as extended
exposure to the sun. The research also found that skin cancers linked to
RDEB may be genetically more similar to head and neck cancers.

"This research adds more evidence to the idea that molecular profiling
modernizes our view of cancer and underscores our need for new
approaches to developing therapies," said Shahrooz Rabizadeh, PhD, Chief
Scientific Officer for NantOmics. "The evidence continues to pile up in
favor of the persistent evolution of immuno-oncology therapies beyond
checkpoint inhibitors to meet the demands of cancer's varied landscape
of molecular profiles."

The study focused on cells of children with RDEB, a condition that makes
skin extremely fragile and prone to blistering and soars. Besides pain
and discomfort of their condition, as well as potential scarring,
patients often develop an aggressive form of skin cancer.

About NantOmics:

NantOmics, a member of the NantWorks ecosystem of companies, uses the
technology that drives NantHealth's GPS Cancer platform to deliver
molecular analysis capabilities with the intent of providing actionable
intelligence and molecularly driven decision support for cancer patients
and their providers at the point of care. NantOmics is the first
molecular analysis company to pioneer an integrated approach to
unearthing the genomic and proteomic variances that initiate and drive
cancer, by analyzing both normal and tumor cells from the same patient
and following identified variances through from DNA to RNA to protein to
drug. NantOmics has a highly scalable cloud-based infrastructure capable
of storing and processing thousands of genomes a day, computing genomic
variances in near real-time, and correlating proteomic pathway analysis
with quantitative multi-plexed protein expression analysis from the same
micro-dissected tumor sample used for genomic analysis. For more
information please follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About GPS Cancer™

GPS Cancer™ is a unique, comprehensive test available through
NantHealth. GPS Cancer integrates tumor/normal DNA and RNA sequencing,
with enhanced expression analysis and bioinformatics of complex biologic
pathway systems, including the immune system which provides oncologists
with a comprehensive molecular profile of a patient's cancer to inform
personalized treatment strategies. GPS Cancer testing is conducted in
CLIA-certified and CAP-accredited laboratories. For more information,
visit www.gpscancer.com.

View Comments and Join the Discussion!